Universal updated phase 1 data validates the feasibility of allogeneic anti-BCMA ALLO-715 therapy for relapsed/refractory multiple myeloma Meeting Abstract
| Authors: | Mailankody, S.; Liedtke, M.; Sidana, S.; Matous, J. V.; Chhabra, S.; Oluwole, O. O.; Malik, S. A.; Kumar, S.; Nath, R.; Anwer, F.; Cruz, J. C.; Jagannath, S.; Htut, M.; Raje, N. S.; Siegel, D. S.; Karski, E. E.; Lovelace, W.; Lourbakos, A.; Nandakumar, S. P; Balakumaran, A.; Hari, P. |
| Abstract Title: | Universal updated phase 1 data validates the feasibility of allogeneic anti-BCMA ALLO-715 therapy for relapsed/refractory multiple myeloma |
| Meeting Title: | 63rd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 138 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 11-14 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-11-23 |
| Language: | English |
| ACCESSION: | WOS:000736398802191 |
| DOI: | 10.1182/blood-2021-145572 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 651 -- Hybrid meeting, also took place online -- Source: Wos |
